At a glance
- Originator Abbott Laboratories
- Class Anti-inflammatories
- Mechanism of Action Adenosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain; Rheumatoid arthritis
Most Recent Events
- 31 Mar 2005 Discontinued - Preclinical for Pain in USA (PO)
- 31 Mar 2005 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)
- 04 Mar 2003 No development reported - Preclinical for Pain in USA (PO)